The Relationships Between MASLD, Extrahepatic Multimorbidity, and All-Cause Mortality in the UK Biobank Cohort - Takeaways - MDSpire

The Relationships Between MASLD, Extrahepatic Multimorbidity, and All-Cause Mortality in the UK Biobank Cohort

  • By

  • Qi Feng

  • Chioma N Izzi-Engbeaya

  • Andrea D Branch

  • Benjamin H Mullish

  • Pinelopi Manousou

  • Mark Woodward

  • June 10, 2025

  • 0 min

Share

  • 1

    Metabolic dysfunction–associated steatotic liver disease (MASLD) affects approximately one third of the global population.

  • 2

    In the UK Biobank study, 29.9% of participants were identified with MASLD, showing a higher prevalence of multimorbidity.

  • 3

    MASLD is linked to increased mortality, with a hazard ratio of 1.16, particularly affecting females and those with fewer long-term conditions.

  • 4

    Each additional long-term condition at baseline raised mortality risk by 30% in MASLD patients and 38% in non-MASLD patients.

  • 5

    The study highlights the need for targeted interventions to address long-term conditions in individuals with MASLD to improve health outcomes.

Original Source(s)

The Relationships Between MASLD, Extrahepatic Multimorbidity, and All-Cause Mortality in the UK Biobank Cohort

  • by Qi Feng, Chioma N Izzi-Engbeaya, Andrea D Branch, Benjamin H Mullish, Pinelopi Manousou, Mark Woodward

  • June 10, 2025

Related Content

From risk factors to molecular targets: clinical associations and molecular docking insights into phthalate-associated diabetic retinopathy

Metformin’s Potential Role in Posterior Capsule Opacification

Common diabetes therapy reaches intraocular lens tissue and may help limit PCO, says newly published data

  • March 30, 2026

  • 3 min
Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026